Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compassionate Use of Tenalisib in Hematological Malignancies
NCT03711604Phase 2Completed
- Sponsor
- Rhizen Pharmaceuticals AG
- Start
- Nov 2018
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of tenalisib in hematological malignancy, sponsored by Rhizen Pharmaceuticals AG. Started Nov 2018; status: completed.
02
Drugs
tenalisib
03
Conditions
hematological malignancy
Beyond the preview
Go deeper on NCT03711604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03711604.